3
Clinical Trials associated with Gamma-PN3A Phase 1, Randomised, Active-controlled, Blinded, Dose-ranging Study of the Safety, Tolerability, and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine (Gamma-PN3) in Elderly Participants
Phase 1 double- blind randomised active comparator dose escalating study of Gamma PN3 in the elderly
A Safety and Immunogenicity Extension Study of GPNV-001
A 6 and 12 month safety and immunogenicity study of participants in study GPNV-001, a novel whole-cell pneumococcal vaccine.
A Phase 1, Randomised, Placebo-controlled, Double-blind, Sequential Ascending-dose Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine (Gamma-PN3) in Healthy Adults
This is a randomised placebo-controlled first-in-man dose-ranging study to determine safety and markers of efficacy.
100 Clinical Results associated with Gamma-PN3
100 Translational Medicine associated with Gamma-PN3
100 Patents (Medical) associated with Gamma-PN3
100 Deals associated with Gamma-PN3